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2Abstract
The trematode Schistosoma mansoni is a causative agent of schistosomiasis, the second most 
common parasitic disease of humans after malaria.  Calcium homeostasis and calcium-mediated 
signalling pathways are of particular interest in this species.  The drug of choice for treating 
schistosomiasis, praziquantel, disrupts the regulation of calcium uptake and there is interest in 
exploiting calcium-mediated processes for future drug discovery.  Calmodulin is a calcium sensing 
protein, present in most eukaryotes.  It is a critical regulator of processes as diverse as muscle 
contraction, cell division and, partly through interaction with voltage-gated calcium channels, intra-
cellular calcium concentrations.  S. mansoni expresses two highly similar calmodulins – SmCaM1 and 
SmCaM2.  Both proteins interact with calcium, manganese, cadmium (II), iron (II) and lead ions in 
native gel electrophoresis.  These ions also cause conformational changes in the proteins resulting 
in the exposure of a more hydrophobic surface (as demonstrated by anilinonaphthalene-8-sulfonate 
fluorescence assays).  The proteins are primarily dimeric in the absence of calcium ions, but 
monomeric in the presence of this ion.  Both SmCaM1 and SmCaM2 interact with a peptide 
corresponding to an IQ-motif derived from the α-subunit of the voltage-gated calcium channel 
SmCav1B (residues 1923-1945).  Both proteins bound with slightly higher affinity in the presence of 
calcium ions.  However, there was no difference between the affinities of the two proteins for the 
peptide.  This interaction could be antagonised by chlorpromazine and trifluoperazine, but not 
praziquantel or thiamylal.  Interestingly no interaction could be detected with the other three IQ-
motifs identified in S. mansoni voltage-gated ion calcium channels.
Keywords:  calcium binding protein; calmodulin antagonist; voltage-gated calcium channel; blood 
fluke; neglected tropical disease
3Abbreviations
ANS, anilinonaphthalene-8-sulfonate
BS3, bis(sulfosuccinimidyl)suberate
CPZ, chlorpromazine
PZQ, praziquantel
rmsd, root mean square deviation
SmCaM1, one of the two calmodulins from S. mansoni
SmCaM2, one of the two calmodulins from S. mansoni
TFP, trifluoperazine
ThA, thiamylal
W7, N-(6-Aminohexyl)-5-chloro-1-naphthalenesulfonamide hydrochloride
4Introduction
Calmodulin is a small (~17 kDa) calcium sensor protein which is found in almost all eukaryotes.  It is 
known to function in calcium signalling in a wide range of distinct cellular processes including muscle 
contraction, calcium homeostasis and inflammation [1].  Structurally, it consists of two globular 
heads, linked by an extended α-helix [2, 3].  Within each globular head are two EF-hand motifs which 
are capable of binding calcium and other divalent cations.  The EF-hand is a compact structure in 
which the polypeptide backbone turns tightly, creating a space for divalent cation binding in which 
carbonyl and carboxylate ligands point inwards to coordinate the ion [4, 5].  On binding calcium ions, 
calmodulin undergoes a conformational change in which the protein’s surface becomes more 
hydrophobic [6-8].  This facilitates interaction with a range of target molecules [9, 10].  Typically, 
the linker helix partially “melts” enabling the two heads to move closer together and for the protein 
to wholly or partially wrap around extended target sequences.
One key target motif is the IQ-motif.  This has the consensus sequence IQxxxRGxxxR; however 
considerable variation on this sequence is possible.  The motif is found in proteins as diverse as 
myosin superfamily members, the cytoskeleton regulating IQGAP family proteins and voltage-gated 
ion channels.  The effect of calcium ions on calmodulin-IQ-motif interactions varies.  In some cases, 
the interaction requires calcium ions whereas others are promoted in the absence of calcium and 
some are independent of calcium concentrations [11-13].  Structurally, the IQ-motif typically forms 
an extended α-helix which calmodulin (and structurally similar proteins such as myosin light chains) 
can wrap around [14-17].
Voltage-gated calcium channels (Cav channels) regulate the influx of calcium into cells.  These 
channels are multimeric protein complexes consisting of a large, pore-forming Cav α1 subunit, 
attached to two smaller auxiliary subunits, termed Cav β and Cav α2δ [18]. The cytoplasmic β subunit 
5acts to modulate the activity of the channel whilst directing expression to the plasma membrane 
[19], whereas the heterodimeric α2δ subunit acts as a transmembrane receptor for various anti-
epileptic drugs [20]. Although both auxiliary subunits play important regulatory roles in the protein 
complex, it is the α1 subunit that primarily defines the pharmacological and functional profile of the 
channel. Cav α1 subunits are defined by the type of current they gate, and can be distinguished by 
various kinetic parameters or pharmacological characteristics [18]. For example, long-lasting, L-type 
Cav channels have a high voltage of activation (HVA), and a slow inactivation rate [18]. These 
channels are formed by Cav1-type α1 subunits (including the Cav1.1, Cav1.2, Cav1.3 and Cav1.4 sub-
families) and are further characterised by their sensitivity to various antagonistic drugs, most 
notably those of the dihydropyridine (DHP) class [21-23].  Mammals typically express a complement 
of ten Cav α1 subunits, whereas invertebrate species tend to contain a single representative from 
each Cav1, Cav2 and Cav3 subtypes [18, 24]. However, these trends do not apply to members of the 
Schistosoma genus [25]. Initial work revealed the existence of three Schistosoma mansoni voltage-
gated calcium channels (SmCav), designated SmCav1A, SmCav2A and SmCav2B [26]. Subsequent 
annotation of the S. mansoni genome indicated the existence of a fourth, designated SmCav1B [27].  
Furthermore, as SmCav1 α1 subunits (SmCav1A and SmCav1B) share highest sequence identity with 
vertebrate Cav1 (L-type) channels, whereas SmCav2 isotypes (SmCav2A and SmCav2B) share highest 
sequence identity with Cav2 (P/Q, N and R-type) channels, this suggests that schistosomes encode 
four HVA channels, yet possess no equivalent to the LVA (T-type) channel [25]. 
Depending on local or global calcium ion concentrations, Ca2+-CaM binding at the C-terminal region 
of the Cav α1 subunit can either attenuate the influx of calcium ions through the channel pore, in a 
process called calcium-dependent inactivation (CDI), or it can promote calcium influx, in a process 
called calcium-dependent facilitation (CDF) [28-32]. Furthermore, the C-terminal region of the α1 
subunit is believed to function as a binding site for apo-CaM, allowing constitutive tethering of the 
6calcium sensor [28, 33, 34].
Schistosomiasis (bilharzia) is a parasitic disease which results from infections by worms from the 
genus Schistosoma.  It is second only to malaria in terms of the number of humans affected by 
parasitic infections and the majority of cases are in the developing world [35]. In schistosomes (and 
some other helminth parasites) disruption of calcium homeostasis is one consequence of the 
administration of the anthelminthic drug praziquantel (PZQ) [36-42].  A number of authors have 
hypothesised that PZQ acts by disruption of voltage-gated calcium channels; however, the 
molecular details of this have yet to be discovered [38, 39].  Nevertheless, this suggests that calcium 
signalling molecules are worthy of further study as potential targets for novel anti-schistosomal 
drugs.  It has been shown previously that Schistosoma mansoni has two calmodulin isotypes.  These 
two isotypes are highly similar, differing only by two amino acid residues towards the C-termini [43].  
Despite this high level of similarity the available evidence suggests that the proteins are derived 
from separate genes [43].  The calmodulin antagonist trifluoperazine (TFP) reduced miracidium-to-
sporocyst transformation in a dose-dependent manner suggesting a critical involvement for one or 
both calmodulin isotypes in this process [43].  This compound has also been shown to collapse the 
tegumental membrane potential and to disrupt the ultrastructure of the tegument [44].  Earlier 
work demonstrated that calmodulin is also required for egg hatching in S. mansoni [45].  Here, we 
present the biochemical characterisation of the two known calmodulin isotypes from S. mansoni 
including the identification of a likely binding site in one of the parasite’s voltage-gated calcium 
channels.
Materials and Methods
Molecular modelling
Initial molecular models of SmCaM1 and SmCaM2 in the “closed” conformation were generated 
7using Phyre2 in the intensive mode [46, 47].  These were energy minimised using YASARA 
(http://www.yasara.org) [48].  To generate calcium-bound forms of the two proteins, the minimised 
models were aligned (using PyMol, www.pymol.org) with the most similar structure identified by 
Phyre2 (potato calmodulin, 1RFJ [49]).  New models were generated by saving either SmCaM1 or 
SmCaM2 with the calcium ions from 1RFJ.  To generate the final, calcium-bound structures, these 
models were then minimised with YASARA.  The templates for the remaining S. mansoni calmodulin 
(SmCaM1 and SmCaM2) homology models were:  Ca2+-CaM in the “open” conformation, Rattus 
rattus calmodulin (PDB: 3CLN) [50]; Ca2+-CaM in the “collapsed” conformation, Bos taurus 
calmodulin (PDB: 1PRW) [51]; Apo-CaM in the homodimeric state, Rattus norvegicus calmodulin 
(PDB: 1QX5) [52]; Ca2+-CaM-IQ peptide complex, Homo sapiens calmodulin in complex with an IQ 
peptide derived from the human Cav1.2 channel α1 subunit, HsCav1.2 (PDB: 2F3Y) [16]. These 
structures were viewed and edited in PyMol, version 4.40 (http://www.pymol.org/) using the 
mutation function to alter the sequences to match the S. mansoni ones. The resulting SmCaM1 and 
SmCaM2 models were then saved as new molecules, and then computationally solvated and energy 
minimised using the YASARA [48].  To validate the models, Ramachandran plots were calculated 
using RAMPAGE (http://mordred.bioc.cam.ac.uk/~rapper/rampage.php) [53].
Expression and purification of SmCaM1 and SmCaM2
Expression vectors for S. mansoni calmodulins (SmCaM1 and SmCaM2) were generated by ligation 
independent cloning into pET-46 Ek/LIC (Merck, Nottingham, UK).  This vector introduces 
nucleotides encoding a hexahistidine tag (amino acid sequence MAHHHHHHVDDDDK) into the 
coding sequence.  Amplicons were generated by PCR from S. mansoni adult-stage cDNA 
(Schistosomiasis Resource Centre, distributed by BEI Resources, Manassas, VA, USA; Strain PR-1; 
NR-48633; Lot 62506671) using primers designed according to the manufacturer’s instructions.  
These amplicons were purified and inserted into the vector using the manufacturer’s protocol.  DNA 
8sequences were verified (GATC Biotech, London).
Recombinant S. mansoni calmodulin proteins were expressed in E. coli Rosetta(DE3) (Merck). 
Competent cells were transformed according to the manufacturer’s instructions, and plated 
overnight on LB-agar plates supplemented with 100 µg ml-1 ampicillin, and 34 µg ml-1 
chloramphenicol. For the recombinant expression of both SmCaM1 and SmCaM2, single colonies 
were picked and cultured overnight, shaking at 30 °C, in 5 ml of LB (Miller) broth (Foremedium, UK), 
supplemented with 100 µg ml-1 ampicillin and 34 µg ml-1 chloramphenicol. These cultures were used 
to inoculate larger cultures (1 L LB broth, supplemented with 100 µg ml-1 ampicillin and 34 µg ml-1 
chloramphenicol), which were grown at 22 °C for a further 10 hours before induction with 0.4 g IPTG 
(1.7 mM final concentration). IPTG-induced cultures were grown overnight at 16 °C, and cells 
harvested by centrifugation at 4200 g for 30 min. Pellets were resuspended in approximately 20 ml 
of buffer R (50 mM Hepes-OH, pH 7.5; 150 mM sodium chloride; 10 % (v/v) glycerol), and frozen at 
- 80 °C until required.
Recombinant proteins were purified by cobalt affinity chromatography, as previously described 
[54]. Briefly, cells were thawed, disrupted by sonication (five 30 s pulses at 100 W, separated by 30 
s intervals to prevent overheating), and the suspension clarified by centrifugation (22,000 g for 20 
min).  The sonicate was passed through a 1 ml cobalt-agarose column under gravity (His-Select, 
Sigma, Poole, UK), which had been equilibrated in buffer A (50 mM Hepes-OH, pH 7.5; 500 mM 
sodium chloride; 10 % (v/v) glycerol).  The column was washed with approximately 40 ml of buffer 
A, and recombinant proteins were eluted with two 2 ml aliquots of buffer C (buffer A supplemented 
with 250 mM imidazole).  Protein fractions were dialysed overnight (on ice) in 1 L of dialysis buffer 
(50 mM Hepes-OH, pH 7.5; 150 mM sodium chloride; 1 mM DTT; 10 % (v/v) glycerol.). Dialysed 
protein samples were then aliquoted, and frozen at -80 °C until required.  Once thawed, protein 
9stocks were either used immediately or discarded. Protein concentration was determined by the 
method of Bradford, using bovine serum albumin (BSA) as a standard [55].
Expression and purification of other proteins
The coding sequence for Fasciola hepatica calmodulin, FhCaM1 (GenBank: AM412546), was PCR-
amplified from adult F. hepatica cDNA and inserted into pET-46 Ek/LIC.  The production of plasmids 
for the expression of human calmodulin (HsCaM) (GenBank: AAD45181) and human galactokinase 
(HsGALK1) (RefSeq accession: NP_000145) has been described previously [56, 57].  These proteins 
were expressed and purified essentially as described for SmCaM1 and SmCaM2.
Native gel electrophoresis
In accordance with previous studies, the calcium chelator, EGTA, was routinely used to remove 
endogenously bound calcium ions from protein preparations:  SmCaM proteins were then 
reconstituted with metal ions in a two-fold molar excess to ensure saturating binding conditions 
[54, 58-62].  For ion-binding assays, protein aliquots (10-40 µM) were incubated at 22 °C for 30 min 
in the presence of either EGTA, or EGTA and a two-molar excess of the appropriate ion solution, and 
diluted in Buffer R to a final volume of 10 µl. After this time, 10 µl of the appropriate native loading 
buffer was added (20 % (v/v) native running buffer pH 6.6; 20 % (v/v) glycerol; 5 % (w/v) 
bromophenol blue; 1 %(w/v) DTT). The protein samples were then electrophoresed at 20 mA 
(constant current) on 15 % continuous native-polyacrylamide gels at pH 6.6 (25 mM histidine, 30 
mM MOPS) with a run-time of approximately 1 h.
For SmIQ peptide-binding assays, SmCaM1, SmCaM2, human calmodulin (HsCaM1), and F. hepatica 
calmodulin (FhCaM1) (10 µM), were incubated for 30 min at 20 °C in the presence of either EGTA (2 
mM), or EGTA (2 mM)/calcium chloride (4 mM). After this time, the appropriate peptide solution (5-
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160 µM) was added, and samples were incubated for a further 60 min before the addition of native 
loading buffer and electrophoresis on 15 % continuous native-PAGE at pH 6.6. Assays with the 
control protein, HsGALK1, were performed under similar conditions, except this protein was 
resolved under 10 % discontinuous native-PAGE at pH 8.8 (25 mM Tris-HCl, 250 mM glycine).  For 
drug inhibition assays, SmCaM1 and SmCaM2 (10 µM), were incubated in the presence of EGTA (2 
mM) and calcium chloride (4 mM) for 30 min at 20 °C, prior to the addition of SmIQ3 (20 µM), and 
the appropriate drug (100-600 µM in DMSO). DMSO controls (1% (v/v)) were performed under the 
same conditions. Samples were then incubated for a further 1 h before the addition of native loading 
buffer and electrophoresed under the same conditions as ion-binding assays.
Gels were stained with Coomassie blue (0.25% (w/v) Coomassie Brilliant Blue R250 dissolved in 10% 
(v/v) acetic acid/45% (v/v) ethanol) for at least 1 h and then destained (5% (v/v) ethanol; 7.5% (v/v) 
acetic acid) until the background was clear.
Analytical gel filtration
Analytical gel filtration was performed as previously described [63]. Briefly, protein samples (260-
300 µl) were incubated at 20 °C for 15 min in the presence of buffer R, supplemented with either 
EGTA (2 mM) or calcium chloride (2 mM). Samples were then chromatographed on a Sephacryl S-
300 column (Pharmacia) of total volume (Vt) 73.8 ml, which had been equilibrated with the 
appropriate buffer. Flow rates were fixed at approximately 0.6 – 1.0 ml min-1. Fractions (0.6 – 1.0 
ml) were collected, weighed and analysed for protein content using the method of Bradford [55]. 
These values were plotted against the running volume, and the elution volume (Ve) was determined 
from the absorbance maximum on the resulting chromatogram.  Standard proteins, with known 
molecular mass (kDa) and Stoke’s radii (Rs), were used to calibrate the column:  serum albumin (67.0 
kDa; Rs = 2.55 nm), chymotrypsinogen (25.0 kDa; Rs = 2.09 nm) and ribonuclease (13.7 kDa; Rs = 1.64 
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nm) (GE Healthcare). Their elution volumes (Ve) were used to calculate partition coefficients (Kav), 
according to the following equation:  Kav = (Ve - V0) / (Vt – V0), where V0 is the void volume (18.5 ml, 
as determined using blue dextran) (GE Healthcare). These values were then plotted against Rs 
values, so that unknown Stoke’s radii could be interpolated from the standard curve using linear 
regression, as implemented in GraphPad Prism, v6.0 (GraphPad Software Inc, CA, USA).  To correct 
for the effects of hydrodynamic volume, sedimentation coefficients (S20, w) were determined in 
silico, by submitting the corresponding homology model to WinHydroPRO 1.00 
(http://leonardo.inf.um.es/macromol/programs/hydropro/hydropro.htm) [64]. Sub-unit 
stoichiometry (n) was then estimated using the following equation: nM = S20, w NA (6πη Rs)/ (1 - ν2ρ), 
where M is the molecular mass (in Daltons), NA is Avogadro's number (6.023 × 1023 mol-1), η is the 
viscosity of the solvent (0.01 g cm-1 s-1), ν2 is the partial specific volume (0.73 g cm3 g-1), and ρ is the 
density of the solvent (1.0 g cm-3) [65, 66].
Fluorescence spectroscopy
Intrinsic fluorescence data were collected on a Spectra Max Gemini XS fluorescence plate-reader, 
using SOFTmax PRO software. Excitation was set to 280 nm or 290 nm and emission spectra were 
collected from 330 to 400 nm.  All samples were prepared in 10 mM Hepes buffer pH 7.4, 
supplemented with DTT (1 mM). Measurements were performed in triplicate, in 96-well black 
plates, and spectra were background-corrected using control samples with the appropriate buffer 
solution.  
For peptide-binding assays, SmIQ3 peptide (14 µM) was titrated with SmCaM1 or SmCaM2 (2-28 
µM) either in the presence of EGTA (0.5 mM), or in the presence of EGTA (0.5 mM)/calcium chloride 
(1.0 mM). Mixtures were incubated for 1.5 h at 37 °C, before analysis. Control assays with HsGALK1 
(10 µM) were run alongside.  Since SmCaM interactions caused a shift in peptide emission spectra, 
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as well as a change in fluorescence intensity, the extent of binding was not proportional to changes 
in the fluorescence signal at any given wavelength. Thus, spectra were integrated from 330 to 400 
nm, and fluorescence data normalised by dividing the total area under the spectrum in the absence 
of quencher (F0), by the total are under the spectrum at each titration point (F) [67]. Fluorescence 
data were analysed according to the following linear Stern-Volmer equation:  F0/F = 1 + Ksv [Q], 
where [Q] is the concentration of quencher (either SmCaM1 or SmCaM2) and Ksv is the Stern-Volmer 
quenching constant [68]. Linear regressions were implemented in GraphPad Prism, v6.0.
Anilinonaphthalene-8-sulfonate (ANS; Sigma Aldrich, Poole, UK) is a fluorescent probe which binds 
preferentially to surface-exposed hydrophobic regions of proteins [69]. ANS fluorescence data were 
collected with excitation set to 350 nm, and emission spectra collected from 410 to 510 nm. 
Measurements were performed in triplicate, in 96-well black plates, and spectra were background-
corrected using control samples with the appropriate buffer solution.  Stock solutions of ANS were 
prepared in sterile, deionized water, and shielded from light at all times; working dilutions were 
prepared in 10 mM Hepes buffer pH 7.4.  SmCaM1 and SmCaM2 (10 µM), were incubated for 30 
min at 37 °C in Hepes buffer (10 mM, pH 7.4), supplemented with either EGTA (2 mM), or EGTA (2 
mM) and the appropriate ion solution (4 mM). After this time ANS (36 µM) was added to each well, 
to a final volume of 100 µl. Samples were mixed, covered (to eliminate direct light), and incubated 
for a further 60 min at 37 °C. 
Statistical analysis
Datasets were analysed by one-way ANOVA with statistical significance thresholds set at P < 0.05 
and P ≤ 0.01. All analyses were performed in GraphPad Prism 6 using Tukey’s post hoc test for 
multiple comparisons.  Linear regression data were analysed by analysis of covariance (ANCOVA).
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Results
Predicted structures of SmCaM1 and SmCaM2
The globular lobes of calmodulins are typically connected by a central “linker helix”, of 
approximately eight turns in length. As this region displays considerable conformational flexibility 
in solution, CaM can adopt an array of conformations under different cellular conditions [70-73].  In 
the apo form CaM adopts a compact, “closed” conformation, whereby hydrophobic patches at the 
N- and C-terminal lobes are sequestered from the surrounding solvent [1, 74]. As the cellular 
concentration of calcium ions rises, binding at each EF-site elicits a structural rearrangement of the 
flanking helices; the central linker helix extends, and hydrophobic clefts are exposed at the N- and 
C-terminal lobes [3, 50]. Thus, calcium-saturated calmodulin (Ca2+-CaM) adopts an elongated, 
“open” conformation.  However, these conformational states are not static structures. Ca2+-CaM 
exists in a dynamic equilibrium between the elongated conformation and a compact, or “collapsed”, 
conformation. The latter represents a lower entropy state associated with ligand binding [51]. 
Transitions between these conformational states (and numerous intermediate/partially bound 
states) are achieved via structural alterations at the short connecting loop, which joins the N- and 
C-terminals of the linker helix [51, 75].
SmCaM homology models were constructed to mimic each of these conformational states (Fig. 1). 
Ca2+-SmCaM proteins were modelled in the “open” conformation, as this reflects the experimentally 
determined structure of vertebrate CaM in the presence of excess calcium (PDB: 3CLN) [50]; and in 
the “collapsed” conformation, based on the bovine brain calmodulin structure (PDB: 1PRW) [51], as 
this is likely to represent the intermediate state of Ca2+-CaM, upon interaction with binding partners 
and/ or antagonists.  Apo-SmCaM proteins were modelled in the “closed” conformation (Fig. 1), 
thereby reflecting nuclear magnetic resonance (NMR) studies, which indicated that the terminal 
lobes of CaM adopted a globular conformation in the absence of calcium ions [6]. Furthermore, as 
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vertebrate CaM has been shown to form compact dimers in the absence of calcium ions (PDB: 1QX5) 
[52], SmCaM proteins were also modelled as homodimers.  Ca2+-SmCaM structures, modelled in the 
“open” conformation, aligned well with the template structure (with an average root mean square 
deviation, rmsd of 0.455 Å, over approximately 875 equivalent atoms), and with each other (with 
an rmsd of 0.349 Å, over 1941 equivalent atoms). The same was true of Ca2+-SmCaM proteins 
modelled in the “collapsed” conformation, which showed high structural similarity to the template 
(with an average rmsd of 0.254 Å, over approximately 828 equivalent atoms), and to each other 
(with an rmsd of 0.264 Å, over 1050 equivalent atoms). Dimeric models also aligned well with the 
template structure (with an average rmsd of 0.507 Å, over approximately 1815 equivalent atoms), 
and with each other (with an rmsd of 0.367 Å, over 3880 equivalent atoms), as did apo-SmCaM 
monomers (with an rmsd of 0.551 Å, over 1840 equivalent atoms).
Examination of the Ramachandran plots for each calcium-bound structure showed that 99.3 % of 
residues were in “favoured” regions of the plot, whereas only 0.7 % were in “allowed” regions. 
Likewise, Ramachandran plots for each apo-SmCaM structure indicated that, on average, 98.5 (± 
0.3) % of residues were in favoured regions of the plot, and 1.6 (± 0.3) % were in allowed regions. 
Although there were no “outliers” in any of the homology models analysed, it should be noted that 
the X coordinating position of the SmCaM EF-2 site was positioned within an allowed region of the 
plot in most structures (data not shown), thereby suggesting that the second EF-hand may be 
distorted from the ideal conformation around this position.
Expression and purification of SmCaM1 and SmCaM2
The two Schistosoma mansoni calmodulins (SmCaM1 and SmCaM2) were expressed in, and purified 
from, Escherichia coli Rosetta(DE3) cells, with protein yields of approximately 6 mg of purified 
protein per litre of bacterial culture (Figure 2). For comparative purposes, similar protocols were 
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employed successfully for the expression and purification of the Fasciola hepatica calmodulin, 
FhCaM1, and the Homo sapiens calmodulin, HsCaM (data not shown).
Ion binding properties of SmCaM1 and SmCaM2
Numerous studies have demonstrated that vertebrate CaM can be activated by a range of metal 
ions, besides calcium [76-81]. Thus, the ion binding properties of S. mansoni calmodulins (SmCaM1 
and SmCaM2) were investigated. Native-PAGE assays revealed that the electrophoretic mobility of 
SmCaM1 and SmCaM2 was increased in the presence of EGTA (compared to untreated protein 
samples), whereas the addition of calcium ions to the EGTA treatment group reduced the 
electrophoretic mobility of each protein to that of the untreated sample (Fig. 3a).  This suggested 
that both SmCaM proteins had pre-associated with calcium ions during the expression/ purification 
process, and that both were capable of reversibly binding this ion under the conditions of the assay.  
In addition to calcium ions, SmCaM1 and SmCaM2 were shown to interact with cadmium, 
manganese, iron and lead ions (Fig. 3a). No ion interactions could be detected in the presence of 
magnesium, strontium, barium, cobalt, copper, nickel, zinc or potassium under the conditions of 
this assay.
Previous structural studies have demonstrated that vertebrate CaM transitions from a globular 
“closed” conformation to an extended “open” conformation as calcium ions reach saturating levels 
[3, 50].  This structural transition is characterised by an increase in surface hydrophobicity at the N- 
and C-terminal lobes of the protein [74]. Thus, ANS fluorescence methodologies were employed to 
ascertain whether similar calcium-dependent conformational changes occur in S. mansoni 
calmodulins, thereby validating the choice of template structures for SmCaM homology models, and 
informing subsequent analytical gel filtration experiments. Since SmCaM1 and SmCaM2 were 
observed to bind cadmium, manganese, iron and lead ions in native-PAGE assays (Fig. 3a), these 
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ions were included in ANS fluorescence experiments; whereas magnesium (which had no 
observable effect on the electrophoretic mobility of either protein) (Fig. 3a), was included as a 
negative control.
ANS displayed the expected fluorescence emission spectrum when incubated in the presence of 
SmCaM1 or SmCaM2, and excited at 350 nm:  a broad peak was observed, with a fluorescence 
intensity maximum (λmax) at approximately 460 nm (Fig. 3b). When SmCaM proteins were incubated 
with ANS in the presence of EGTA, the fluorescence intensity at λmax was lower than that of the 
calcium treatment group, thereby suggesting that calcium chelation caused structural 
rearrangement in each protein, characterised by a net gain in surface hydrophobicity.  This 
observation is consistent with a structural transition from the “closed” to the “open” conformation. 
A similar effect was observed with cadmium, manganese, iron and lead ions, but not with 
magnesium ions (Fig. 3b), reflecting the ion binding patterns of SmCaM1 and SmCaM2 under non-
denaturing native-PAGE (Fig. 3a).  Interestingly, these results showed a difference from those 
obtained by native gel electrophoresis.  While the untreated and EGTA-treated proteins had 
different mobilities on native gels, they had quite similar ANS fluorescence spectra (with the EGTA-
treated proteins having only marginally lower fluorescence intensity).  The explanation for this is 
not completely clear.  It may reflect the nature of the purified, recombinant proteins.  It is possible 
that the recombinant proteins bind calcium resulting in an overall change in shape and charge 
(reported in the native gel assay), and the exposed hydrophobic patches associate with non-polar 
bacterial molecules (e.g. membrane lipids which will be released when the cells are disrupted during 
purification) which block the association of ANS.  EGTA treatment would remove the calcium ions, 
reverse the exposure of the hydrophobic regions and release any bound hydrophobic molecules 
(which would be diluted to be much lower concentration in the assays than during purification).
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Dimerisation of SmCaM proteins
Previous studies have demonstrated that vertebrate CaM forms non-covalently linked homodimers 
in the apo-state [52, 82]. Analytical gel filtration methodologies were employed to estimate the 
oligomeric state of S. mansoni calmodulins in the presence and absence of calcium ions. Since 
human galactokinase (HsGALK1), exists predominantly as a monomer in vitro [57], this protein was 
used as an internal control.  Examination of the elution profiles, revealed that SmCaM1 and SmCaM2 
eluted at a lower volume in the presence of 2 mM EGTA, than in the presence of 2 mM calcium 
chloride, implying that oligomerisation was promoted in the absence of calcium ions. Indeed, apo-
SmCaM proteins eluted at approximately twice the molecular mass of their calcium-bound 
counterparts, yielding taller and sharper elution peaks than those observed in the presence of 
calcium ions (Fig. 4). This indicated a shift from the dimeric to the monomeric state upon calcium 
chelation, accompanied by an increase in conformational heterogeneity. The molecular mass of the 
control protein (HsGALK1) was estimated at approximately 42 kDa using this method; this is 
consistent with the molecular mass of the HsGALK1 monomer (43 kDa as estimated from the 
primary sequence of the hexahistidine-tagged recombinant form).
However, the results from ANS fluorescence assays suggest substantial conformational changes on 
ion binding and unbinding.  To correct for any possible effects of these changes on the elution 
profiles, sedimentation coefficients were computationally estimated from SmCaM homology 
models using WinHydroPRO v1.00 [64].  Ca2+-SmCaM structures (modelled in the “open” 
conformation), generated computationally estimated sedimentation coefficients of 1.69 S for Ca2+-
SmCaM1, and 1.67 S for Ca2+-SmCaM2; whereas dimeric models generated sedimentation 
coefficients of 2.87 – 2.89 S (Table 1). Stoke's radii (Rs) were estimated from the gel filtration data 
as 2.47 nm for Ca2+-SmCaM1, and 2.61 nm Ca2+-SmCaM2. These values yielded an estimated subunit 
stoichiometry of 0.95 – 0.99 for the SmCaM monomers, and 1.61 – 1.71 for the SmCaM dimers 
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(Table 1). Given that monomeric models represented a better fit to the experimental data than 
dimeric models, this provided further evidence that both SmCaM proteins eluted as monomers in 
the presence of calcium ions.  Conversely, apo-SmCaM structures (modelled in the “closed” 
conformation), generated computationally estimated sedimentation coefficients of 1.82 S for apo-
SmCaM1, and 1.83 S for apo-SmCaM2 (Table 1).  Both proteins had an Rs value of 3.29 nm and this 
yielded a subunit composition of approximately 1.4 for the SmCaM monomer, and 2.15 - 2.16 for 
the SmCaM dimer (Table 1). As dimeric models represented a better fit to the experimental data 
than monomeric models, this provided further evidence that SmCaM proteins eluted as 
homodimers in the absence of calcium ions.  The same methodologies were applied to the control 
protein, HsGALK1, which was modelled as a monomer and as a dimer, using the experimentally 
determined structure (PDB: 1WUU) [83]. Monomeric HsGALK1 yielded an estimated subunit 
stoichiometry of approximately 0.98, whereas the HsGALK1 dimer yielded a subunit composition of 
approximately 1.5 (Table 1). As expected, the monomeric model represented a better fit to the 
experimental data, thereby validating the analytical methods employed in this study.
Identification of IQ-motifs in S. mansoni voltage-gated calcium channels
Cav α1 subunits contain a conserved, α-helical motif directly termed the isoleucine-glutamine (IQ) 
motif. The IQ motif spans a region of approximately 20 amino acids, but the core of the motif is 
defined by an 11-residue consensus sequence, IQxxxBxxxxB, where B signifies a positively charged 
amino acid residue (arginine or lysine), and x signifies a variable amino acid [11].  The IQ motif is a 
known binding site for CaM. Indeed, the Cav1.2 channel IQ domain been implicated as a possible 
tethering site for apo-CaM [84], whereas numerous studies have shown that Ca2+-CaM interactions 
with the IQ domain are essential for the CDI and CDF of both Cav1-type and Cav2-type channels [85, 
86].  Moreover, crystallographic studies have demonstrated that the affinity and orientation of the 
Ca2+-CaM-Cav IQ domain interaction is dictated by the overall charge distribution of the IQ motif, as 
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well as the spacing and positioning of key hydrophobic/aromatic “anchor” residues [16, 17, 87, 88].
We identified four IQ-motifs in S. mansoni Cav α1 subunits and designated SmIQ1 - SmIQ4 (Fig. 5), 
which display an unusual pattern of distribution. For instance, whereas SmIQ1, SmIQ3 and SmIQ4 
are each “conventionally” positioned within the C-terminal regions of SmCav1A, SmCav1B and 
SmCav2A, respectively (Fig. 5), SmCav2B seemingly lacks an IQ motif, containing a stop codon directly 
upstream from the expected position of the IQ consensus sequence [26]. Furthermore, the SmCav1A 
α1 subunit contains a second IQ motif (SmIQ2) directly following the first [26], resulting in an 
unusually extended IQ domain. Although IQ motifs often occur as tandem repeats in the muscle 
protein myosin [11], this phenomenon is not commonly observed in Cav channels, and appears to 
be unique to parasitic flatworms.  Based on these sequence analyses, synthetic peptides (23-mers) 
were designed to incorporate the four IQ-motifs (bold sequences in Fig. 5).
Interaction of SmCaM1 and SmCaM2 with IQ-motifs from voltage-gated calcium channels
Native-PAGE assays revealed that the electrophoretic mobility of SmCaM1 and SmCaM2 was 
decreased in the presence of SmIQ3 (compared to the untreated protein sample) (Fig. 6a). These 
effects occurred both in the presence and absence of calcium ions, but could not be detected in the 
presence of SmIQ1, SmIQ2 or SmIQ4, nor in the presence of the control protein, HsGALK1 (Fig. 6a), 
thereby implying a specific, calcium-independent interaction between both S. mansoni calmodulins 
and SmIQ3. Moreover, as interactions were resolved as discrete shifts on native gels, this indicated 
the formation of a stable, long-lived binding complex with the SmIQ3 peptide.  A similar outcome 
was observed in native-PAGE assays with the F. hepatica calmodulin, FhCaM1, and vertebrate CaM 
(as exemplified by the human isotype, HsCaM) (Fig. 6a), indicating that the SmIQ3 peptide forms a 
stable binding complex with generic, 148-amino acid calmodulins from distant phyla.
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Semi-quantitative native-PAGE confirmed the occurrence of a dose-dependent interaction between 
SmCaM1 or SmCaM2 and the SmIQ3 peptide (Fig. 6b). As expected, both calmodulin isotypes 
underwent a similar reciprocal exchange from the higher- to the lower-mobility species, with 
increasing concentrations of SmIQ3 (Fig. 6b), indicating a comparable affinity for the peptide. These 
effects were absent in assays with SmIQ1, SmIQ2 or SmIQ4 (data not shown).  However, whereas 
the graded transition from the higher- to the lower-mobility state resulted in the disappearance of 
the unbound protein band at a 1:4 (protein:peptide) molar ratio in the presence of EGTA (2 mM), 
this interchange occurred at a 1:2 (protein:peptide) molar ratio in the presence of a 2-fold molar 
excess of calcium chloride (Fig. 6b). This suggests that both SmCaM proteins may have a marginally 
lower affinity for SmIQ3 in the apo-state, than they do in the calcium-bound state.
As the two SmCaM proteins do not contain tryptophan residues, they emit negligible fluorescence 
when excited at wavelengths within the 280 to 295 nm range. Therefore, in intrinsic binding assays 
with SmIQ3, the bulk of the fluorescence signal can be attributed to two tryptophan residues, 
located at positions 3 and 7 of the SmIQ3 peptide.  Initial tryptophan fluorescence assays utilised an 
excitation wavelength of 295 nm, to limit interference from SmCaM tyrosine residues [68]. 
However, these preliminary experiments resulted in complete quenching of the SmIQ3 fluorescence 
signal upon addition of SmCaM1/ SmCaM2, which could not be accurately quantified (data not 
shown). Thus, excitation was set to 280 nm, and emission measured from 330 to 400 nm.  The SmIQ3 
peptide yielded a characteristic fluorescence emission spectrum, when excited at 280 nm.  A broad 
peak was observed, with a fluorescence emission intensity maximum (λmax) at approximately 355 
nm (Fig. 7). When SmIQ3 was titrated with increasing concentrations of SmCaM1 or SmCaM2, the 
fluorescence intensity at λmax was substantially lower than that of the untreated peptide (Fig. 7). 
These effects were dose-dependent, and occurred both in the presence and absence of calcium 
ions, implying that the two tryptophan residues of the peptide had come into close contact with 
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quenching groups, located within the protein.  This, in turn, was consistent with a net reduction in 
solvent-exposed (free) peptide.  Fluorescence quenching also caused a blue-shift in emission 
spectra, yielding broader, flatter peaks than those observed in the presence of free peptide (Fig. 7), 
thereby implying that SmIQ3 was positioned in a more hydrophobic environment upon binding 
SmCaM1 or SmCaM2 [68]. These data are consistent with assimilation of the peptide within the 
CaM hydrophobic pocket, leading to the formation of a compact binding complex.
Since native-PAGE assays had suggested that S. mansoni calmodulins had a higher affinity for SmIQ3 
in the presence of calcium ions, than they did in the apo-state (Fig. 6b), intrinsic fluorescence data 
were quantified according to the Stern-Volmer (SV) relationship (Fig. 7). Briefly, fractional 
fluorescence was plotted as a function of SmCaM concentration, to quantify the change in SmIQ3 
fluorescence resulting from complex formation [68], and the strength of the interaction between 
the quencher (SmCaM1 or SmCaM2) and fluorophore (SmIQ3) was reported as the SV quenching 
constant (Ksv), which was determined from the slope of the resulting linear plot (Table 2).  It should 
be noted that Ksv contains both static (complex-forming) and dynamic (collisional) components [68]. 
However, since native-PAGE experiments had indicated that SmCaM proteins formed a stable 
binding complex with the SmIQ3 peptide (Fig. 6), fluorescence datasets were considered to 
represent primarily static quenching. Indeed, the linear nature of each SV plot suggested that static 
quenching was dominant in the system (Fig. 7), with negligible contributions from dynamic/ 
collisional quenching.  In this scenario, Ksv can be assumed to be equal to the association constant 
(Ka) between the fluorophore and quencher [68].  Statistical analysis of the linear regression of the 
SV data, demonstrated a significant difference between treatment groups (p < 0.001; ANCOVA; n = 
3), which, upon analysis of the Ksv association constant for each treatment group, represented a 
small, but significant increase in SmCaM-SmIQ3 affinity in the presence of calcium ions, compared 
to the EGTA treatment group (p < 0.05; ANOVA; n = 3) (Table 2). This provided further indication 
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that SmIQ3 binding was promoted in the presence of calcium ions. Furthermore, as Ksv association 
constants for complex formation were not significantly different between SmCaM1 and SmCaM2 
datasets (Table 2), suggesting that both calmodulins had a comparable affinity for the SmIQ3 
peptide.
Non-denaturing native-PAGE was used to screen for interactions between SmCaM proteins and the 
calmodulin antagonists, CPZ, W7, TFP and ThA (Fig. 8a).  As the actions of these calmodulin 
antagonists have been shown to be calcium-dependent [89, 90], binding assays were performed 
under calcium-saturating conditions.  Thus, in each gel image, higher-mobility bands correspond to 
Ca2+-SmCaM, whereas lower-mobility bands represent the Ca2+-SmCaM-SmIQ3 complex (Fig. 8a). 
Given that previous studies have indicated that the antischistosomal drug, PZQ, interacts with a 
myosin regulatory light chain (MLC), which bears certain structural similarity to calmodulin [91], this 
drug was tested alongside the others (Fig. 8a).  Both calmodulins underwent a partial exchange from 
the lower- to the higher-mobility species, in the presence of CPZ and TFP (Fig. 8a), implying an 
inhibitory effect on protein-peptide interactions.  These inhibitory effects could not be detected in 
the presence of PZQ, W7 or ThA, nor in the presence of the delivery vehicle, DMSO (Fig. 8a), 
indicating a specific interaction with the phenothiazine drugs, CPZ and TFP. Moreover, semi-
quantitative native-PAGE assays demonstrated that both SmCaM proteins underwent a graded 
exchange from the lower- to the higher-mobility species with increasing concentrations of CPZ or 
TFP, consistent with a dose-dependent antagonism of the SmCaM-SmIQ3 binding complex (Fig. 8b).
Discussion
The two calmodulins of S. mansoni have very similar biochemical properties.  In the experiments 
described here no differences in ion binding, conformational change in response to ions, 
dimerization, IQ-motif binding or antagonism of this binding was detected.  Given the highly similar 
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sequences, this might be expected.  Nevertheless, it raises the question as to why the organism 
expresses two highly similar isotypes of the same protein from two separate genes.  Previous work 
has demonstrated that both isotypes are expressed in the same life cycle stages [43].  This suggests 
that the two isotypes do not have stage-specific roles as has been suggested for the tegumental 
allergen-like proteins from this species or the β-tubulin isotypes in F. hepatica [92-94].  The S. 
mansoni calmodulins also show some differences in properties to the proteins from other 
trematodes.  F. hepatica expresses at least three calmodulin isotypes [95, 96].  Of these, FhCaM1 is 
the most similar to SmCaM1 and SmCaM2 in sequence and predicted structure.  However, this 
protein (and FhCaM2) interacts with magnesium ions in native gel electrophoresis, unlike SmCaM1 
and SmCaM2 [95].  Clonorchis sinensis calmodulin also interacts with both calcium and magnesium 
ions [97].  There is also no evidence for dimerization of FhCaM1, although there is some evidence 
from gel electrophoresis for dimerization of FhCaM3 [96].  TFP and W7 both interact with FhCaM1 
and FhCaM3, but not FhCaM2 [96].  In this work, we demonstrated that FhCaM1 (and HsCaM) also 
bound to the SmIQ3 peptide.  Identical sequences occur in voltage-gated calcium channels in 
Opisthorchis viverrini, Clonorchis sinensis and Echinococcus granulosus suggesting that these also 
represent sites for calmodulin binding in these parasites.  FhCaM1 also interacts with a sequence 
from a plasma membrane calcium ATPase (PMCA).  This sequence is predicted to adopt an α-helical 
conformation, but it is not an IQ-motif [98].  Therefore, it seems likely that SmCaM1 and SmCaM2 
also bind to (and, most likely, regulate) PMCA in addition to voltage-gated calcium channels.
Despite containing three L-type Cav channel IQ motifs (SmIQ1, SmIQ2 and SmIQ3) (Fig. 5), 
bioinformatics data suggest that only two of these sequences represent functional binding sites for 
CaM.  SmIQ1 and SmIQ3 are 100% conserved in trematodes, and share considerable (75 %) 
sequence identity with the IQ motifs of mammalian L-type, Cav1.2 channels.  Both motifs adhere to 
the IQ consensus sequence, and both contain a full complement of six aromatic anchors. Moreover, 
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structure prediction using Phyre2 predicted a high α-helical propensity for both IQ sequences, a 
structural characteristic common to many CaM target sites [99].  Conversely, SmIQ2 is not well 
conserved in platyhelminths, and bears little resemblance to the IQ motifs of mammalian Cav1-type 
channels. Indeed, this vestigial sequence contains a one residue deletion at position four, a 
conspicuous paucity of aromatic anchors, and (according to structure prediction by Phyre2) a largely 
disordered secondary structure (data not shown). Thus, whereas SmIQ1 and SmIQ3 seemingly fit 
the criteria for a canonical CaM binding site, it may be hypothesised that SmIQ2 has either lost the 
ability to bind calmodulin, or does so via a novel, non-canonical anchoring scheme.  Interestingly, 
the sole non-L-type Cav channel IQ motif in S. mansoni (SmIQ4) also deviates considerably from the 
IQ consensus sequence (Fig. 5). Indeed, this unusual motif may span either one of two overlapping 
positions. For example, multiple sequence alignments indicate that the core of the SmIQ4 consensus 
sequence begins with the isoleucine residue at position 0 (i.e 1581IYENWQMNKST1591). In this 
scenario, a lack of positively charged amino acids means that SmIQ4 has a net charge of zero 
(whereas mammalian Cav2 channel IQ motifs typically have a net charge of +1 or +2). Moreover, 
four (out of five) critical residues of the IQ consensus sequence are lost, including the central and 
terminal basic residues of the motif, and a conserved aromatic anchor at position three which has 
been shown to be energetically important for Ca2+-CaM binding in mammalian Cav2-type channels 
[87].  Alternatively, given that the first position of the IQ motif is ambiguous for a hydrophobic or 
aromatic residue in myosin proteins [11], the core of the SmIQ4 consensus sequence could begin 
with the tryptophan residue at position four (i.e. 1585WQMNKSTGNKK1595). In this scenario, the 
distribution of anchoring positions is disrupted, but the motif has a more conventional charge 
distribution (with a net charge of +3), and two (out of five) positions of the IQ consensus sequence 
are maintained.
The lack of binding between SmCaM and IQ1 was, therefore, unexpected.  Native-PAGE assays tend 
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to detect binding events which are stably maintained throughout the duration of the experiment, 
and fluorescence quenching relies on changes to the environment of fluorescent amino acid 
residues to infer binding.  Therefore it is possible that some SmIQ peptides interact with calmodulin 
in a way which involves rapid association and dissociation combined with binding in a way which 
does not affect the environment of a fluorophore.  It is also possible that high affinity binding with 
calmodulin to some of the IQ-motifs requires additional sequences from the protein, which are not 
present in the relatively short peptides used here.  Nevertheless, given that SmIQ1 and SmIQ3 differ 
from each other by four “variable” positions of the consensus sequence (at positions 2, 6, 8 and 9), 
and that three of these positions distinguish the SmIQ1 sequence from higher-affinity sites, such as 
the Cav1.2 IQ motif (or SmIQ3) (Fig. 5), it is possible to speculate that these substitutions endow the 
SmIQ1 peptide with an inherently lower affinity for CaM.
Vertebrate CaM can be antagonised by a range of drugs, some of which are used in a clinical setting 
for the treatment of psychiatric disorders [100]. For example, the antipsychotic drug chlorpromazine 
(CPZ), has been shown to bind to multiple sites on the CaM structure [89], antagonising the protein’s 
function in a dose-dependent manner [101, 102].  Similar effects were observed with the 
phenothiazine derivative, trifluoperazine (TFP) [90, 103]. Indeed, structural studies of the TFP-CaM 
binding complex have demonstrated that at least one drug molecule binds within a large “V-shaped” 
hydrophobic binding pocket, formed by the collapse of the N-and C-terminal lobes of the protein 
[103, 104]; stabilising a compact conformation that occludes interactions with peptide ligands [103, 
105].  Furthermore, in vitro bioassays have demonstrated an enhanced motility/ stunted growth 
phenotype in F. hepatica juveniles treated with TFP.  These effects are consistent with those 
observed upon silencing of calmodulin via RNA inactivation (RNAi) [106].  Since both CPZ and TFP 
were observed to antagonise SmCaM-SmIQ3 complex formation in a concentration-dependent 
manner (Fig. 8), this implies a druggable interaction between SmCaM and the SmCav1B calcium 
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channel. Indeed, as previous studies have demonstrated that S. mansoni larvae react to TFP 
treatment via a dose-dependent reduction in miracidial transformations [43], it is tempting to 
speculate that these phenotypic effects stem, at least in part, from the inhibition of interactions 
between calmodulin and the IQ domain of the SmCav1B α1 subunit.
Given that exposure of adult S. mansoni worms to the antischistosomal drug, PZQ, results in 
disruption of calcium homeostasis [107], components of parasite calcium signalling pathways 
(including binding partners of CaM), have attracted considerable attention as the possible molecular 
targets of PZQ [39], and as putative candidates for novel treatment strategies against 
schistosomiasis. The biochemical analyses presented here provide no indication of an interaction 
between S. mansoni calmodulin and praziquantel.  Thus, the interaction between calmodulin and 
the SmCav1B calcium channel is unlikely to represent a molecular target for this drug. Moreover, 
the calmodulin is highly conserved through different animal phyla and there is high sequence 
identity between SmIQ3 and the IQ motifs of mammalian Cav channels.  This means that the 
antagonism of the SmCaM-SmCav1B complex, while possible, is unlikely to be sufficiently selective 
for the parasite over the host.  Thus, this interaction may not represent a viable target for 
anthelmintic development.  Nevertheless, there are important functional roles for SmCav1B in 
parasite calcium signalling processes.  Therefore, these observations do not eliminate the possibility 
that schistosome Cav channels represent viable candidates for the design of novel anthelmintics.  
Thus, proteins unique to trematodes which are involved in the functioning or regulation of these 
channels may represent intriguing candidates for future drug development.
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Figure legends
Figure 1:  The predicted structures of SmCaM1 and SmCaM2.  Top: a schematic representation of 
the domain organisation of SmCaM proteins; N, denotes the N-terminal domain; C, denotes the C-
terminal domain. Red represents the SmCaM N-lobe (residues 1-64); green represents the central 
helix region (residues 65-92); blue represents the SmCaM C-lobe (residues 93-148); pink represents 
the flexible connecting loop (residues 77-81). Protein structures are displayed in cartoon format, 
and calcium ions are depicted as yellow spheres. Images were constructed in PyMol, version 4.40. 
Apo-SmCaM1 was modelled in the “closed” state, using Phyre2 in the intensive mode [47]. Calcium-
bound SmCaM1 was modelled in the “collapsed” state, using bovine CaM as a template (PDB: 1PRW) 
[51]. Calcium-bound SmCaM1 was also modelled in the “open” state, using R. rattus calmodulin as 
a template (PDB: 3CLN) [50]. All models were energy minimised in YASARA [48].
Figure 2:  Expression and purification of SmCaM1 and SmCaM2.  Recombinant SmCaM1 and 
SmCaM2 were purified from E. coli Rosetta(DE3) competent cells and this process was monitored 
by 15 % SDS-PAGE: M, molecular mass ladder (sizes in kDa to the left of the gels); U, sample from 
uninduced cells, prior to IPTG induction; I, sample from induced cells prior to harvesting; S, sample 
from soluble sonicate after clarification by centrifugation; W, samples from two washes with buffer 
A; E, samples from two elutions with buffer C.
Figure 3:  Ion binding by SmCaM1 and SmCaM2.  (a) SmCaM1 and SmCaM2 (10 µM) were resolved 
on 15 % continuous native-PAGE at pH 6.6 [108]. U, Untreated proteins (U), E, proteins treated with 
EGTA (2 mM). Ion-treated proteins (as indicated on the panels at the top of this figure), were 
incubated in the presence of 2 mM EGTA and 4 mM of the appropriate ion solution.  Reduced 
mobility, compared to the EGTA-treated protein, is evidence of ion binding.  (b) SmCaM1 and 
SmCaM2 (10 µM) were incubated either in the presence of EGTA (2 mM), or in the presence of EGTA 
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(2 mM), and the appropriate ion solution (4 mM) together with ANS (36 µM). U, untreated protein 
samples are shown in light blue; E, EGTA treatment group is shown in red; ion treatment groups are 
shown as follows: calcium (green), cadmium (purple), manganese (orange), magnesium (black), iron 
(brown), and lead (pink). The fluorescence spectra shown are plots the mean fluorescence intensity, 
measured in arbitrary units (AU), over a range of emission wavelengths. Assays were baseline 
corrected using an equal volume of buffer, containing the appropriate concentration of EGTA/ion 
solution.  An increase in fluorescence intensity is associated with the exposure of hydrophobic 
regions on the surface of the protein, resulting from interaction with the ion and subsequent 
conformational change.  This was seen with calcium, lead, cadmium and, to a lesser extent, iron (II) 
and manganese (II) ions.  Magnesium ions cause almost no change in the ANS fluorescence spectra 
(and the line is partly obscured by that for the untreated protein) and EGTA treatment causes a 
modest decrease.
Figure 4:  The oligomeric state of SmCaM1 and SmCaM2 is dependent on calcium ions  The top 
graph shows the elution of SmCaM proteins in the presence of either EGTA (2 mM), or calcium 
chloride (2 mM) along with the control protein, human galactokinase (HsGALK1). Samples from each 
fraction were treated with Bradford’s reagent, and absorbance was measured at 595 nm in order to 
estimate protein content. Elution volumes (Ve) were determined from absorbance maxima.  Apo-
SmCaM1 is shown in blue, apo-SmCaM2 in red, Ca2+-SmCaM1 in green; Ca2+-SmCaM2 in purple and 
the control protein, HsGALK1, in orange.  The calibration graphs derived from data obtained using 
proteins of known molecular mass (M) and Stoke’s radius (RS) are shown below.  R, Ribonuclease; 
C, Chymotrypsinogen; A, serum albumin.  All calculations and analyses were performed in GraphPad 
Prism, version 6.0.
Figure 5:  IQ-motifs from the voltage-gated calcium channels of Schistosoma mansoni  Multiple 
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sequence alignments were generated in Mega 6.06, using MUSCLE [109]. The IQ-motifs SmIQ1 and 
SmIQ2 are located in the SmCav1A α1 subunit, SmIQ3 is located in SmCav1B, and SmIQ4 is located in 
SmCav2A. The numbers in parentheses denote the position of the first amino acid in each aligned 
sequence.  The “IQ consensus” sequence (top), was derived from [110], where “x” represents any 
amino acid. To facilitate comparisons between different sequences, the first isoleucine residue of 
the IQ motif is referred to as “position 0” and other residues are numbered according to their N-
terminal (-), or C-terminal (+) location, relative to position 0. Stars represent conserved “anchor” 
positions [17, 87]. Bold residues represent 23-mer, synthetic SmIQ peptide sequences.  Accession 
numbers:  Human Cav1.1 (AAI33672); Human Cav1.2 (AAI46847); Human Cav1.3 (AAA58402); Human 
Cav1.4 (NP_005174); Human Cav2.1 (O00555); Human Cav2.2 (AAA51898); Human Cav2.3 
(NP_001192222); S. mansoni SmCav1A (AAK84312); S. mansoni SmCav1B (CCD59069); S. mansoni 
SmCav2A (AAK84311); S. mansoni SmCav2B (AAK84313).
Figure 6:  Interaction of SmCaM1 and SmCaM2 with IQ-motifs from voltage-gated calcium 
channels  (a) Gel images showing the migration patterns of SmCaM1 and SmCaM2 (10 µM) on 15 % 
continuous native-PAGE at pH 6.6 [108]. Untreated (U) SmCaM proteins, were treated with either 
EGTA (2 mM) (left-hand gels), or EGTA (2 mM) and calcium chloride (4 mM) (right-hand gels), in the 
presence of SmIQ peptides, SmIQ1, SmIQ2, SmIQ3 and SmIQ4 (labelled 1-4), at a final concentration 
of 160 µM. Similar protocols were applied to the F. hepatica calmodulin, FhCaM1 (GenBank: 
AM412546), and vertebrate CaM, as exemplified by the H. sapiens calmodulin, HsCaM (GenBank: 
AAD45181). H. sapiens galactokinase, HsGALK1 (RefSeq: NP_000145) was used as a negative 
control.  (b) Gel images showing the migration patterns of tSmCaM1 and SmCaM2 (10 µM) on 15 % 
continuous native-PAGE at pH 6.6. Untreated (U) SmCaM proteins, were treated with either EGTA 
(2 mM), or EGTA (2 mM) and calcium chloride (4 mM) (as labelled), in the presence of rising 
concentrations of the SmIQ3 peptide (final concentrations 5, 10, 20, 40, 80 and 160 µM). Higher-
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mobility (bottom) bands represent unbound SmCaM1 or SmCaM2; lower-mobility (top) bands 
represent the SmCaM-SmIQ3 peptide complex. The second lane (labelled “IQ3”), represents the 
peptide-only (160 µM) control. Assays with SmIQ1, SmIQ2 and SmIQ4 did not display a mobility shift 
under the same conditions (data not shown).
Figure 7:  Affinity of SmCaM1 and SmCaM2 with IQ-motifs from voltage-gated calcium channels 
SmIQ3 peptide (14 µM) was incubated either in the presence of EGTA (0.5 mM), or in the presence 
of EGTA (0.5 mM)/calcium chloride (1 mM), and treated with rising concentrations of SmCaM1 or 
SmCaM2 (2-28 µM). U, untreated protein samples are depicted in blue. Assays were excited at 280 
nm, and emission recorded from 330 to 400 nm. Intrinsic fluorescence spectra (left column) were 
recorded for each assay, and were baseline corrected using the appropriate buffer and 
concentration of SmCaM1 or SmCaM2.  Since SmCaM1 and SmCaM2 both lack tryptophan residues, 
these spectra largely report on the environment of tryptophans in the peptides.  Quenching of the 
fluorescence is evidence for peptide-CaM interaction.  Stern-Volmer plots (right column) were used 
to determine fluorescence quenching constants and, subsequently, to compare the affinities of the 
peptides and proteins (see Results). Fractional fluorescence (Fo/F) was determined by dividing the 
area under the untreated (U) spectrum by the respective quenched spectrum. Linear regressions 
were performed in GraphPad Prism, version 6.0 (GraphPad Software Inc, CA, USA).
Figure 8:  Antagonism of the interaction of SmCaM1 and SmCaM2 with IQ-motifs by calmodulin 
antagonists  (a) Gel images showing the migration of SmCaM1 (top) and SmCaM2 (bottom) on 15 % 
continuous native-PAGE at pH 6.6 [108]. SmCaM proteins (10 µM), were treated with EGTA (2 mM) 
and calcium chloride (4 mM), in the presence of the SmIQ3 peptide (20 µM). The first lane 
represents untreated (U) SmCaM1 or SmCaM2, the second lane (IQ3), represents the untreated 
Ca2+-SmCaM-SmIQ3 binding complex. SmCaM-SmIQ3 binding complexes were treated with DMSO 
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(D), at a final concentration of 1 % (v/v), or the following drugs: praziquantel (PZQ), chlorpromazine 
(CPZ), N-(6-Aminohexyl)-5-chloro-1-naphthalenesulfonamide hydrochloride (W7), trifluoperazine 
(TFP), or thiamylal (ThA), each at a final concentration of 500 µM.  (b) Gel images showing the 
migration patterns of SmCaM1 and SmCaM2 under 15 % continuous native-PAGE at pH 6.6. SmCaM 
proteins (10 µM), were treated with EGTA (2 mM) and calcium chloride (4 mM), in the presence of 
the SmIQ3 peptide (20 µM). The first lane represents untreated (U) SmCaM1 or SmCaM2, the 
second lane (IQ3), represents the untreated Ca2+-SmCaM-SmIQ3 binding complex. SmCaM-SmIQ3 
complexes were treated with rising concentrations of either CPZ or TFP (as labelled; 0.1 to 0.6 mM, 
rising in increments of 0.1 mM).
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Tables
Table 1:  Dimerisation of SmCaM1 and SmCaM2 as determined by analytical gel filtration
Apo-SmCaM1 Apo-SmCaM2 Ca2+-SmCaM1 Ca2+-SmCaM2 HsGALK1
Molecular mass determined from primary sequence, Mseq (kDa)
Monomer
Dimer
18.5
37.0
18.5
37.0
18.5
37.0
18.5
37.0
43.3
86.6
Eluction volume, Ve (ml) 25.6 25.6 28.8 28.2 27.3
Stoke’s radius, Rs (nm) 3.3 3.3 2.5 2.6 2.9
Sedimentation coefficient, S20, w (S)
Monomer
Dimer
1.8
2.9
1.8
2.9
1.7
2.9
1.7
2.9
3.5
5.4
Estimated molecular mass, Mest (kDa)
Monomer
Dimer
25.2
39.7
25.3
40.0
17.6
29.8
18.3
31.7
42.3
65.8
Stoichiometry 
Monomer 1.36 1.37 0.95 0.99 0.98
33
Dimer 2.15 2.16 1.61 1.71 1.52
Best fit Dimer Dimer Monomer Monomer Monomer
Apo-SmCaM proteins were treated with EGTA (2 mM), Ca2+-SmCaM proteins were treated with calcium chloride (2 mM). Mseq represents the molecular 
mass of each protein, as determined from the primary sequence, plus the N-terminal His6-tag (see Experimental section). Elution volumes (Ve) were 
used to determine partition coefficients (Kav).  Stokes radii (Rs) were interpolated from the standard curve by comparison with standard proteins using 
linear regression. Mest represents the estimated molecular mass of each protein species. Sedimentation coefficients (S20, w) were estimated in silico 
using WinHydroPRO v1.00 and the most relevant molecular model.
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Table 2:  Stern-Volmer constants for the interaction between S. mansoni calmodulins and SmIQ3
Stern-Volmer constant, Ksv (× 104 M-1) ± SEM
EGTA EGTA/CaCl2
SmCaM1 7.84 ± 0.49 * 11.06 ± 0.65
SmCaM2 7.51 ± 0.61 * 10.6 ± 0.34
Stern-Volmer quenching constants (Ksv) were determined as described in the Experimental section. 
Ksv values for SmCaM-SmIQ3 complexes in the presence of EGTA (0.5 mM) were significantly lower 
than those treated with EGTA (0.5 mM) and CaCl2 (1.0 mM); * p ≤ 0.05; ANOVA; n = 3. 
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M U I S W1 W2 E1 E2
116
66
45
35
25
18
14
116
66
45
35
25
18
14
SmCaM1
SmCaM2
(a)
(b)
SmCaM1
SmCaM2

 IQ consensus:  --------IQxxxRGxxxR----
                  **  *    **  *
SmIQ1  (1528):  GKFYATFLIQNWFREWQKRKMIQKDTR
SmIQ2  (1580):  SSDLTGDEIQRR-RGVDKRDTSGGIFG
SmIQ3  (1923):  GKFYATFLIQEWFRRWKQKKAEEQKAL
Cav1.1 (1521):  GFKYATFLIQEHFRKFMKRQEEYYGYR
Cav1.2 (1613):  GKFYATFLIQEYFRKFKKRKEQGLVGK
Cav1.3 (1604):  GKFYATFLIQDYFRKFKKRKEQGLVGK
Cav1.4 (1581):  GKFYATFLIQDYFRKFRRRKEKGLLGN
 
SmIQ4  (1573):  GKIYAGLLIYENWQMNKSTGNKKNLHQ
Cav2.1 (1954):  GKIYAAMMIMEYYRQSKAKKLQAMREE
Cav2.2 (1954):  GKVYAALMIFDFYKQNKTTRDQMQQAP
Cav2.3 (1866):  GKIYAAMMIMDYYKQSKVKKQRQQLEE
(a) (b)
SmCaM1 (calcium)
SmCaM2 (no calcium)
SmCaM1 (no calcium)
SmCaM2 (calcium)
(a)
(b)
